Raymond James analyst Dane Leone upgraded Regeneron Pharmaceuticals to Outperform from Market Perform with a $950 price target. The analyst sees positive momentum into 2024 following the company’s Q3 report. The most impactful near term catalyst for Regeneron will be the interim analysis of the Phase 3 NOTUS study in COPD planned for Q4 of 2023, the analyst tells investors in a research note. The firm says recent feedback from the FDA was that a positive interim analysis of the NOTUS study in addition to the positive Phase 3 BOREAS results would enable an application submission. It thinks that is reasonable to expect a successful interim analysis from NOTUS.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
- Regeneron Reports Third Quarter 2023 Financial and Operating Results
- Regeneron reports Q3 adjusted EPS $11.59, consensus $10.77
- Notable companies reporting before tomorrow’s open
- REGN Upcoming Earnings Report: What to Expect?